MedStar Lung Cancer Trial: First to Enroll a Patient World-Wide

Jean Flack with patient in conference room, looking over papers

Researchers at the Harry and Jeanette Weinberg Cancer Institute at MedStar Franklin Square Medical Center have again enrolled the first patient in the world in a Phase III study of treatment for non-small cell lung cancer.

Estimated enrollment for “Phase III Randomized, Double-Blind Study of Pembrolizumab plus Epacadostat vs Pembrolizumab plus placebo as First-line Treatment in Patients with Metastatic NSCLC expressing high levels of PDL1” (NCT03322540) is more than 580 patients from around the world. This study will track patient outcomes through progression-free survival and overall survival rates at over 160 locations. This study is sponsored by Incyte Corporation and Merck Sharp & Dohme Corp.

“We were able to enroll the first patient due to the wonderful cooperation of the whole research team – contracts, regulatory, pathology, physicians, research coordinators and pharmacists – it was the efforts of all of these people that made it happen, “ said Suman Rao, MD. “Special recognition goes to Jean Flack for her commitment to this study. She went the extra length and her persistence was what resulted in making this milestone.”

The Weinberg Cancer Institute was also the first in the world to enroll a patient in another Phase III study, “A Randomized, Double-Blind, Phase III Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in First Line Metastatic Squamous Non-small Cell Lung Cancer Subjects (KEYNOTE-407)” (NCT02775435) in 2016.

Congratulations to this dedicated, hard-working team for their commitment to advancing health through research!